Aclaris Therapeutics Hits New 52-Week High of $5.69, Up 403.77%

Aclaris Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 5.69 on July 1, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 403.77% rise over the past year, significantly outpacing the S&P 500's performance of 20.74% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology sector, Aclaris Therapeutics has demonstrated notable activity in the market. With a market capitalization of USD 424 million, the company continues to navigate the competitive landscape of its industry. Despite being loss-making, the stock's impressive year-over-year performance highlights its potential in the market. Key financial metrics include a price-to-book ratio of 4.12 and a debt-to-equity ratio of -0.88, indicating a unique financial structure. However, the company does not offer a dividend yield, which is consistent with many firms in its growth phase. The stock's previous 52-week low was recorded at USD 1.39, underscoring the significant upward trajectory it has experienced.